Search Bar & Filters
Found 89 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting real-world data to assess how well Teleflexs vascular access devices perform and how safe they are when used as intended. These devices include various types such as central venous access devices, midline catheters, peripheral catheters, hemodialysis catheters, and arterial catheters with navigation and tip confirmation features. Some of these devices also have properties to reduce infections and blood clots. The study observes patients who need a vascular access device for therapy or diagnosis. It includes a variety of devices and accessories used for their placement and maintenance. The registry tracks the use and performance of these devices without assigning specific treatments, focusing instead on collecting data from routine clinical use. Participants will be monitored for device-related outcomes including the success of device use without removal due to adverse events within seven days after device removal. The study also evaluates how accurately catheter tip locations are verified immediately after removal. Data collection includes monitoring any device-related adverse events during this period. The trial will continue until December 2034, providing extended observation of device performance and safety.
Actively Recruiting
This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.
Actively Recruiting
This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.
Actively Recruiting
Researchers are evaluating ASP5541, a new form of abiraterone acetate given by muscle injection, in men with advanced prostate cancer. The study compares ASP5541, with or without prednisoneprednisolone, to standard abiraterone acetate tablets plus prednisoneprednisolone. It aims to assess the safety and effectiveness of ASP5541 in men with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer who have not previously received androgen receptor pathway inhibitors. Participants are assigned to one of three groups men with metastatic castration-resistant prostate cancer receive either ASP5541 plus prednisoneprednisolone or abiraterone acetate plus prednisoneprednisolone men with metastatic hormone-sensitive prostate cancer receive either ASP5541 alone or abiraterone acetate with prednisoneprednisolone and Japanese men with either cancer type receive ASP5541 with prednisoneprednisolone. ASP5541 is administered by injection every 12 weeks, prednisoneprednisolone is taken orally once or twice daily depending on cancer type, and abiraterone acetate is taken daily as tablets. All participants continue standard androgen deprivation therapy. During the study, participants will have regular clinic visits for health monitoring and safety checks, with some checking blood pressure weekly at home. Imaging scans and laboratory tests will assess cancer progression and treatment effects. Researchers will measure outcomes such as prostate-specific antigen levels, safety events, testosterone suppression, and cancer progression. The study includes long-term follow-up for up to 84 months and aims to provide detailed information on the safety and efficacy of ASP5541 compared to existing treatments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of intravenously administered YN001 in adults diagnosed with coronary atherosclerosis who are also receiving treatment for cardiovascular risk factors. This multinational, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial aims to compare different doses of YN001 with placebo in this population. Participants will be randomly assigned to receive one of three weekly intravenous treatments YN001 at 40mg, YN001 at 20mg, or a placebo at 0mg. Treatment will be administered once weekly for 13 weeks, totaling 13 doses. The study includes a screeningbaseline period lasting up to 12 weeks, a 12-week blinded treatment phase, followed by a 30-day safety follow-up and a long-term monitoring period lasting approximately 2 years after randomization. During the study, participants will undergo various assessments including imaging scans to measure changes in coronary and carotid artery plaque, blood tests to analyze YN001 concentration and immune responses, and monitoring for major adverse cardiac events. The primary measurement is the relative change in coronary non-calcified plaque volume from baseline to week 13. Safety and immune response will be closely tracked throughout treatment and follow-up, with total participation lasting up to about 2 years.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are evaluating the effectiveness of Vagus Nerve Stimulation VNS Therapy as an additional treatment for people with treatment-resistant depression. The study compares active VNS treatment with a no stimulation control over a 12-month period to see if VNS can reduce depressive symptoms measured by several depression scales. This is a prospective, multi-center, randomized, controlled, and blinded trial involving subjects who have VNS devices implanted. Participants receive the VNS implant, and after at least two weeks, they are randomized to either have the device activated or not activated for the first 12 months. Those in the control group can receive stimulation after 12 months. After the initial 12-month randomized phase, all participants transition into an open-label, long-term study lasting about 5 years. New subjects may also enroll directly into this extension phase. During the trial, participants are assessed regularly using multiple depression rating scales and questionnaires to monitor changes in symptoms, response times, remission, and adverse events. Safety and quality of life measures are also tracked. The study includes thorough monitoring of depressive symptoms and overall functioning for up to 12 months post-randomization, followed by long-term observation for several years.
Actively Recruiting
This research aims to evaluate the long-term effectiveness of donanemab combined with usual care compared to usual care alone in people with early symptomatic Alzheimers disease. The study uses a prospective, observational cohort design where participant management closely resembles real-world practice. It will include assessments linked to historical and ongoing electronic health records and is expected to last about 273 weeks with up to 28 visits. Participants will be divided into two groups one receiving open-label donanemab intravenously along with usual care, and another receiving usual care alone. Usual care includes medications excluding amyloid-targeting agents or non-drug therapies such as watchful waiting. Treatment and observations will follow real-world clinical management over the study duration. During the study, participants will undergo regular assessments including cognitive status, dependence levels, functional abilities, neuropsychiatric symptoms, and living situation changes. Data collection will include semi-annual and annual questionnaires, lifestyle surveys, and monitoring for time to increased dependence or institutionalization. Participants must have a study partner and allow access to their electronic health records for data linkage throughout the study, which may include up to 28 visits over approximately five years.
1-10 of 89
1